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A B S T R A C T
Purpose: Over 90% of all cancer related deaths are due to metastasis. However, current diagnostic tools can't
reliably discriminate between invasive and localized cancers.
Patients and methods: In this proof-of-concept study, we employed the embryonic stem cell marker TRA-1-60
(TRAþ) to identify TRA þ cells within the blood of prostate cancer patients and searched for TRA þ cells in
men with metastatic and localized cancers. We isolated whole peripheral blood mononuclear cells from 26
metastatic prostate cancer patients, from 13 patients with localized prostate cancer and from 17 healthy controls.
Cells were stained for DAPI, CD45 and TRA þ by immunofluorescence and imaged by epi-fluorescence micro-
scopy. Imaged-based software was used both to identify TRA þ cells, and to analyze CD45 levels in TRAþ and
negative cells.
Results: We found high numbers of TRA þ cells within the blood of metastatic cancer patients, whereas healthy
individuals or men with localized prostate cancer showed none or very low numbers of TRA þ cells. Further
analysis of the CD45 levels of TRA þ cells revealed a small population of TRA þ cells with almost undetectable
CD45 levels that were found frequently in metastatic prostate cancer patients. By excluding CD45 positive cells
from the TRA þ cell pool, we were able to refine the assay to be highly specific in identifying men with metastatic
disease. In fact, the difference of CD45 levels between TRAþ and negative cells was a robust measure to
distinguish between men with localized and metastatic prostate cancers in this small patient cohort.
Conclusions: The data suggest that metastatic prostate cancer patient have significant numbers of TRAþ/CD45low
cells which might represent a potential tool for diagnostic assessment in the future.
1. Introduction
Metastatic spread from the primary tumor to a distant organ site is the
leading cause of cancer-related deaths. Prostate cancer is the third
deadliest type of cancer in men, behind lung and colorectal cancer
(source: cancer.org). The standard treatment for men with localized
disease had been prostatectomy and/or different forms of radiation
therapy as well as testosterone deprivation [1]. More recently active
surveillance strategies have been pursued in men to counteract over
treatment. Despite primary treatment with either or both modalities a
substantial number of men will develop metastatic disease. Metastatic
prostate cancer will inevitably progress to castration-resistant prostate
cancer [2, 3]. In prostate cancer, as in other solid tumors, the ability to
predict disease progression with a simple blood test would be of great
utility, both for diagnostic reasons and as a powerful surveillance tool.
Such an assay would provide clinicians with a tool to identify patients
with malignant disease progression at an earlier time point when treat-
ment efforts are more effective.
Podocalyxin is a member of the CD34 family [28]. In healthy tissues,
podocalyxin functions as a regulator for cell-cell contacts and can be
* Corresponding author.
E-mail address: cschafer@mit.edu (C. Sch€afer).
1 Current address: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Contents lists available at ScienceDirect
Heliyon
journal homepage: www.cell.com/heliyon
https://doi.org/10.1016/j.heliyon.2020.e03263
Received 15 February 2018; Received in revised form 4 February 2019; Accepted 15 January 2020
2405-8440/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Heliyon 6 (2020) e03263
found in podocytes of the kidney, within epithelial and vascular cells as
well as on haematopoietic progenitor stem cells [29, 30, 31, 32]. During
cancer progression, podocalyxin plays an important role in extravasation
and intravasation of cancer cells [33]. Expression of podocalyxin in
various cancers such as prostate, breast and gastric highly correlates with
malignant progression and metastasis [34, 35]. TRA-1-60 is a carbohy-
drate addition to podocalyxin and is highly expressed on normal
pluripotent stem cells [10]. For decades TRA-1-60 has been the gold
standard surface marker for human embryonic stem cells [9].
Recent efforts to provide better patient's outcome predictions incor-
porated embryonic stem cell signatures [4]. Such embryonic or plurip-
otent stem cell profiles were found in many cancers such as breast cancer,
glioblastoma, bladder carcinomas [5], in malignant cervical cancer [6],
in brain, lung and colon cancer [7] as well as in prostate cancer [8]. All
these signatures correlated with poor prognosis. There are increasing
evidences in the literature that TRA-1-60 correlates with metastatic
progression in prostate cancer and many other cancers [11, 12, 13, 14,
15, 16]. Based on this, we tested the potential of TRA-1-60 expression as
a marker to develop a blood test which is able to discriminate aggressive,
metastatic prostate cancer from localized prostate cancer and further to
predict disease progression. In summary this study demonstrates the
potential of TRA-1-60 to be a powerful biomarker in order to identify
men with metastatic disease, in contrast to men with localized prostate
cancer.
2. Material and methods
2.1. Patient samples and PBMCs isolation
Patient samples were derived from a tissue bank study which in
consented patients agreed to data collection and serum and whole-blood
samples (BIDMC protocol 2001P-002244, Prostate Cancer Tissue Bank
and Database). PBMCs were isolated fromwhole blood by Ficoll gradient.
Blood was diluted 1:1 with sterile PBS and added on top of Ficoll-Paque
PLUS (GE), followed by spinning at 1600rpm for 30 min at 4 C. PBMCs
were collected, washed with PBS and fixed with 4% PFA for 10 min at
room temperature (RT).
2.2. Staining methods
Cells were fixed in suspension using 4% PFA at RT for 10min and
blocked with 10% goat serum, 3% BSA and Fc blocker (BD Pharmingen,
1:10) in PBS for 30 min at RT. PBMC were incubated with CD45-FITC
(eBioscience, 1:20) and TRA-1-60 (Life technologies, 1:50) in blocking
at 4 C overnight and then stained with Alexa Fluor®594 Anti-Mouse
(Thermo Fisher, 1:200) for 1 h at RT. The negative control was only
incubated with Alexa Fluor®594 Anti-Mouse. Cells were stained with
DAPI and mounted onto slides.
2.3. Imaging
Imaging was performed on a fluorescence Eclipse microscope (Nikon)
equipped with a sCMOS camera, SOLA system and a motorized filter
turret for DAPI, FITC and TexasRed using a 10x Plan Fluor objectives. For
each patient maximal 20 areas and 10 areas of the control were imaged.
The field of view for each area was 1664 μm  1404 μm with a pixel size
of 0.65μm. Exposure times were kept constant between the stained slides
and the controls.
2.4. Image analysis
DAPI images were pre-processed with Gaussian smoothing (sigma¼ 1
pixel) and background subtraction. Otsu thresholding was used to
generate a mask. To separate segmentations containing more than one
nucleus, the watershed algorithm was applied. This mask was used as a
seed label. For efficient processing, segmentations whose areas are larger
than the median of all segmentations were considered for watershed.
To capture the TRA-1-60 signal, areas per each identified nucleus
were enlarged. For this, a newmask was created by Rosin-thresholding of
the pre-processed image yielding a threshold value for DAPI images
smaller than a value from Otsu's method. The mask was dilated by five
pixels to ensure coverage of the entire cell. To label individual nuclei, the
labels obtained in the seed label were propagated to the dilatedmask that
each pixel is attached with the closest label.
The threshold was defined for each patient using the negative control
and setting the detection levels to zero. This threshold was applied to the
images stained for TRA-1-60. The segmentedmaskwas comparedwith the
dilated nuclei mask to count the number of nuclei that contain pixels from
the TRA-1-60 signal. A minimal signal threshold of at least 5 pixels was
applied to all images. CD45 intensity levels were analyzed inside each
dilated nuclei mask for TRA-1-60 positive and negative cells separately.
We extracted 3 different measurements: 1) percentage of TRA þ cells
per image. 2) The number of cells that are both TRAþ and CD45low was
extracted. Mean CD45 levels from all TRA negative cells were calculated
for each patient, which was used to normalize the CD45 levels for all TRA
þ cells. Normalized CD45 levels below 0.3 were considered CD45low.
These numbers were then expressed as numbers of cells normalized to
per 1000 cells. 3) The differences of CD45 levels from TRA þ cells sub-
tracted by the CD45 levels of TRA negative cells. Only patients with at
least three TRA þ cells were included into this analysis.
To calculate the background fluorescence intensity of the CD45
staining we used the negative control and quantified the mean fluores-
cence intensities in the dilated nuclei mask areas. This was calculated
exemplarily in 6 patients and shown in Figure 5.
2.5. Data presentation
Data were analyzed and bar graphs were made using Excel (Micro-
soft). ROC curve analysis was performed using the Prism6 software
(GraphPad).
3. Results
The goal of this study was to test if the embryonic marker TRA-1-60
could be used to discriminate prostate cancer patients with localized or
metastatic diseases. For this purpose, blood samples from patients with
localized or metastatic prostate cancer and from healthy controls were
collected at Beth Israel Deaconess Medical Center (BI), de-identified and
blinded. As a first attempt we tested the FDA-cleared CELLSEARCH®
platform for our purpose in collaboration with the diagnostics team at
Jansson. The CELLSEARCH® CXC kit was used to detect circulating
tumor cells (CTCs) based on the expression of epithelial cell adhesion
molecule (EpCAM). CTCs were then stained for DAPI, Cytokeratin (CK),
CD45, a marker for white blood cells, and TRA-1-60. Based on the clas-
sification of being EpCAMþ/CKþ/CD45-we detected5 CTCs in two out
of 10 analyzed blood samples from patients with metastatic prostate
cancer. Adding TRA-1-60 expression (TRAþ) to the analysis (EpCAMþ/
CKþ/CD45-/TRAþ) we were only able to identify one patient with
metastatic prostate cancer (out of 10) by detection of 5 CTCs (data not
shown). Since the isolation of CTCs from metastatic prostate cancer pa-
tients was not very effective and infrequent we decided to take a more
unbiased approach without any CTC capturing step by using whole pe-
ripheral mononuclear cells (PBMCs) for our analysis. Additionally, we
switched from a flow-based analysis to direct imaging of the stained
PBMCs by fluorescence microscopy combined with high-throughput
image analysis software. Whole PBMCs were isolated, stained for DAPI,
CD45 and TRA-1-60 and thenmounted on imaging slides. The slides were
imaged by fluorescence microscopy and then analyzed by custom-made
software. In summary, the analysis extracted the total number of cells
analyzed; the percentage of TRA þ cells and the mean CD45 intensities
for each TRAþ and negative cells. To validate the software we used the
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embryonal carcinoma cell line Tera-1 since these cells are known to ex-
press TRA-1-60 [10]. Tera-1 cells were stained for DAPI (Figure 1A) and
TRA-1-60 (Figure 1B), imaged and analyzed with our platform
(Figure 1C–E). The nuclei segmentation is shown in Figure 1C and the
TRA-1-60 signal after thresholding is shown in Figure 1D. Once overlaid
the TRA þ cells were identified (Figure 1E). In two independent exper-
iments, the software recognized 95.5% or 91.8% of all analyzed Tera-1
cells as TRA þ cells.
The study cohort comprised 26 patients diagnosed with metastatic
prostate cancer with an age range from 62 to 89 years (Figure 1F). Most
of these patients were undergoing active treatment during the course of
sample collection. The study also included 13 patients diagnosed with
localized, non-metastatic prostate cancer patients ranging from 62 to 88
years of age and one patient who progressed from localized to metastatic
prostate cancer during the study (age 66). Additionally, we included 17
healthy control samples with an age range from 26 to 52 years.
We initially compared the mean percentages of TRA þ cells found in
healthy controls with the mean percentages seen in metastatic or local-
ized prostate cancer patients (Figure 2A). Healthy controls (Figure 2A,
blue) showed mostly low numbers of TRA þ cells ranging from 0% to
2.3%. In 14 of the 17 samples the mean percentage was below 0.04%
with five of them showing no TRA þ cell. In comparison, samples from
metastatic prostate cancer patients contained higher numbers of TRA þ
cells ranging from 0.2% to up to 13.6% (Figure 2A, red). 24 out of the 26
samples showed numbers well above 0.24% with 17 samples having
more than 1.5% of TRA þ cells. None of the samples from metastatic
prostate cancer patients was scored 0%. The samples from localized
prostate cancer patients ranged from 0.002% to 3.1% of TRA þ cells
(Figure 2A, gray). Nine of the 13 samples were scored below 1.5% of TRA
þ cells. The patient who progressed from localized to metastatic prostate
cancer during the study showed 0.8% of all analyzed cells being positive
for TRA-1-60 (Figure 2A, orange).
Figure 1. Validation of the software and overview of
sample cohort– The embryonal carcinoma cell line
Tera-1 was used as positive control to validate the
software (A-E). Cells were fixed and stained for DAPI
(A) and TRA-1-60 (B), Scale bar ¼ 50 μm. These im-
ages were analyzed using the custom-made software.
First, the DAPI image was used to segment the nuclei
(C). Next, the TRA-1-60 signal was thresholded (D)
and overlaid with the nuclei segmentation to identify
TRA-1-60 þ cells (E, TRA þ cells circled in yellow).
(F) Overview of the sample cohort. The italic numbers
refer to a patient that was categorized localized but
progressed during the study to metastatic. yrs ¼ years.
Figure 2. Identification of TRA-1-60þ cells in the blood of healthy controls, metastatic and localized prostate cancer patients – (A) The mean percentage of TRA-1-60
positive (TRAþ) cells were analyzed from whole peripheral blood mononuclear cells taken from 17 healthy controls (blue), 26 metastatic (red), 13 localized (gray)
prostate cancer patients and 1 (orange) localized prostate cancer patient who progressed to metastatic disease during the study. Error bars indicate standard deviation
from n ¼ 20. (B) Receiver operating characteristics (ROC) curves shows diagnostic value and area under the curve comparing the percentages of TRA þ cells from
healthy controls and metastatic prostate cancer patients (black curve) and the percentages from localized and metastatic prostate cancer patients (gray curve).
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Receiver operating characteristic (ROC) curve analysis was used to
test the discriminating power of the percentage of TRA þ cells as a
diagnostic test (Figure 2B). This determined a significant diagnostic
performance to distinguish between healthy controls and metastatic
prostate cancer patients with the area under the curve (AUC) of 0.95, the
confidence interval (CI) between 0.88-1 and a p-value < 0.0001
(Figure 2B, black curve). Comparing the mean percentages of TRAþ cells
from localized with metastatic prostate cancer patients showed an AUC
of 0.79, a CI between 0.64-0.93 and a p-value < 0.004 (Figure 2B, gray
curve). Even though this measure significantly discriminated between
localized and metastatic prostate cancer it only shows a fair diagnostic
performance.
TRAþ cells were detected in all cohorts, although the number of cells
was higher in patient with metastatic disease. Next, we wanted to know if
there is a difference between the cells from the cohorts. Therefore, we
analyzed the mean CD45 levels of all TRA þ cells and blotted the mean
CD45 intensities for TRA þ cells from six healthy controls (Figure 3A,
blue), six metastatic (Figure 3A, red), six localized (Figure 3A, gray)
prostate cancer patients and from the one patient who progressed
(Figure 3A, orange) so that each dot represents one TRAþ cell. We found
a small population of TRAþ cells that had very low CD45 levels (close to
background levels) which was only present in metastatic prostate cancer
patients (Figure 3A, box) and in the one patient who progressed to
metastatic prostate cancer. To investigate this in more detail, we checked
the original images and indeed, TRAþ cells in healthy controls showed a
strong CD45 signal (Figure 3B, white arrows) whereas in metastatic
prostate cancer patients the TRAþ cells stained remarkably less for CD45
(Figure 3C, white arrows).
Next, we plotted the normalized CD45 levels for all TRAþ cells found
in each of the samples (Figure 4A). As seen before (Figure 3A), TRA þ
cells showed a wide range of CD45 levels in all cohorts. We frequently
found TRA þ cells with a mean CD45 intensity below 0.3 AU in meta-
static prostate cancer patients (Figure 4B, red) as well as in the patient
who progressed from localized to metastatic prostate cancer during the
study (Figure 4B, orange). This population of TRA þ cells and almost
undetectable CD45 levels (TRAþ/CD45low) here further defined as below
0.3, was completely missing in all healthy controls (Figure 4B, blue). The
CD45 levels are reported here as low and not as negative since these cells
still showed a slightly higher mean fluorescence intensity compared to
the background staining (Figure 5). Because of this minimal intensity we
could not exclude residual CD45 expression on these cells. More impor-
tantly, only two cells meeting these criteria were found in two of 13
patients with localized prostate cancer (Figure 4B, gray). Since the total
number of cells analyzed varied from sample to sample, we normalized
the numbers of TRAþ/CD45low cells found in each sample to the total
amount of cells analyzed and expressed this measure as TRAþ/CD45low
cells per 1000 cells (Figure 4C). Only two patients with localized prostate
cancer had 0.03 or 0.04 TRAþ/CD45low cells per 1000 cells (Figure 4C,
gray). In comparison, we found TRAþ/CD45low cells in 20 out of 26
patients with metastatic prostate cancer (Figure 4C, red). In two patients
we found high numbers of 1.4 and 2.7 TRAþ/CD45low cells per 1000
cells. The patient who progressed from localized to metastatic prostate
(caption on next column)
Figure 3. TRA-1-60 positive and CD45low cell population is present in meta-
static prostate cancer patients – (A) Boxplots show normalized mean CD45 in-
tensities for TRA-1-60 positive (TRAþ) cells detected per sample ranging from
level 0 to 0.8. Each dot represents one TRA þ cell. Data from six healthy controls
(blue), six metastatic (red) and six localized (gray) prostate cancer patients are
exemplified. The patient that progressed from localized to metastatic during the
study is shown in orange. The box highlights the TRAþ/CD45low cell popula-
tion. Staining for DAPI (blue), CD45 (purple) and TRA-1-60 (white) in cells from
healthy control (B) and metastatic prostate cancer patient (C) show TRA þ cell
indicated by the white arrows. Scale bar ¼ 50 μm. Note that TRA þ cells in
healthy controls show high levels of CD45 and low levels in patients with
metastatic prostate cancer.
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cancer during the study had 0.18 of TRAþ/CD45low cells per 1000 cells
(Figure 4C, orange).
Since we found that the TRAþ/CD45low cell population is frequently
present in metastatic prostate cancer patients, we next wanted to analyze
the overall CD45 levels in TRA negative (TRA-) compared to TRAþ cells.
For this purpose, we analyzed the mean CD45 fluorescence intensities for
all TRA- and all TRA þ cells separately for each sample. First, we plotted
the normalized mean CD45 intensities for one representative data set
from each cohort (Figure 6A). In the healthy control (Figure 6A, blue) as
well as in the sample from a patient with localized prostate cancer
(Figure 6A, gray) the mean CD45 levels were higher in TRA þ cells
compared to cells negative for TRA. Interestingly, this was the opposite in
the sample from one of the metastatic prostate cancer patients
(Figure 6A, red). Here, the TRA þ cells overall showed a lower mean
CD45 intensities. Based on this, we calculated for all samples at least
containing three TRA þ cells, the CD45 intensity differences between
TRAþ and TRA-cells (Figure 6B). If the TRA þ cells had higher CD45
levels the difference showed a positive number. A negative difference
indicates that the TRA þ cells exhibited lower CD45 levels compared to
TRA-cells. Healthy controls (Figure 6B, blue, n ¼ 7) and samples from
localized prostate cancer patients (Figure 6B, gray, n ¼ 11) mostly
showed a positive value. In contrast, the differences in CD45 levels from
patients with metastatic prostate cancer were very low or even negative
(Figure 6B, red, n ¼ 26). The patient who progressed to metastatic
prostate cancer showed a negative value of about -0.12 (Figure 6B, or-
ange). ROC curve analysis determined a highly significant diagnostic
performance to distinguish between healthy controls and metastatic
prostate cancer patients with an AUC of 0.94, a CI between 0.84-1 and a
p-value < 0.001 (Figure 6C, black curve). More interestingly we
compared localized and metastatic prostate cancer samples using ROC
curve analysis (Figure 6C, gray curve). This analysis showed a good
performance with an AUC of 0.84, a CI between 0.70-0.98 and a p-value
< 0.002. With this test there was only poor, non-significant discrimi-
nating power comparing healthy controls and localized prostate cancer
patients (AUC: 0.68, CI: 0.41–0.94, p-value ¼ 0.2, data not shown).
4. Discussion
Most diagnostic, cell-based tests using blood as a source for analysis
focus on the isolation of CTCs. The only FDA–approved CTC-based
diagnostic test for advanced prostate cancer is the CELLSEARCH® sys-
tem [17, 18, 19]. As described before, this test relies on the detection of
CTCs from the blood of patients based on epithelial markers [20].
Although these cells are detected in greater number in men with meta-
static disease, their importance in cancer progression is uncertain. The
transition from an epithelial to a more mesenchymal phenotype highly
correlates with cancer metastasis [21, 22, 23, 24]. Several studies have
discussed the possibility that capture of CTCs based on epithelial features
is likely not optimal to identify cells with metastatic potential [25, 26,
27]. Specifically, mesenchymal-like or stem cell-like CTCs have been
linked to relapse and metastasis. For us it was a concern that we detected
5 CTCs (EpCAMþ/CKþ/CD45-) in only two out of 10 analyzed blood
samples from metastatic prostate cancer patients. With the goal to
develop an assay to discriminate metastatic from localized prostate
Figure 4. TRA-1-60þ/CD45low cell population highly correlates with metastatic prostate cancer – (A) Complete data set of normalized mean CD45 intensities for all
TRA-1-60 positive (TRAþ) cells detected per sample. Each dot of the boxplots represents one TRA þ cell. The black lines indicate the mean and the whiskers the
standard deviation. Healthy controls (blue), metastatic (red) and localized (gray) prostate cancer samples. The patient that progressed from localized to metastatic
during the study is shown in orange. (B) shows a zoom in of the data shown in (A) highlighting the TRAþ/CD45low cell population. In (C) the counts of TRAþ/CD45low
cells were normalized to the total number of cells analyzed and displayed as number of TRAþ/CD45low cells per 1000 cells for each healthy control (blue), metastatic
(red), localized (gray) prostate cancer samples and for the patient who progressed (orange).
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cancer we decided to move to a more unbiased approach and based our
analysis on the staining of whole PBMCs without any pre-selection step.
This is the first study to report the finding of cells within the blood of
metastatic prostate cancer patients that are positive for the embryonic
marker TRA-1-60. These cells showed almost undetectable CD45 levels.
Overall, we want to point out that we don't know the origin of this cell
population or if these cells are indeed disseminated cancer cells or even a
group of haematopoietic progenitor CD34þ stem cells. For these reasons
we refrained throughout the manuscript to call these cells CTCs and
rather only referred to them as TRAþ/CD45low cells. It would be very
interesting in future studies to determine the origin and a potential
tumorigenicity of this cell population. As these cells (TRAþ/CD45low)
were found frequently in men with metastatic disease and less in patients
with localized prostate cancer, this population of cells may be of use as a
diagnostic but also as a surveillance tool. At this point we can only
speculate about the origin of these cells. To further determine the nature
of the cells more detailed follow-up studies would be required.
In our study, we scored one patient metastatic 4 month before the
metastatic site was detected by conventional methods. A body scan 2
month before the analyzed blood sample was drawn, appeared also
Figure 5. Mean CD45 fluorescence intensity was analyzed in 6 datasets from 6 different patients (1–6). Background intensity (grey) was calculated from PBMCs
treated with only secondary antibody. CD45 levels were analyzed from PBMCs stained for CD45 and CD45 mean intensities were blotted for TRA-1-60þ/CD45low
(red) and TRA-1-60þ/CD45high (blue) population. Standard errors show standard deviation.
Figure 6. Difference in CD45 levels of TRA-1-60 positive minus negative cells is a good diagnostic measure to distinguish between localized and metastatic prostate
cancer – (A) Mean CD45 levels in TRA-1-60 negative (TRA-) are lower compared to TRA-1-60 positive (TRAþ) cells in healthy controls (blue) and in localized prostate
cancer patients (gray). Contradictory, in metastatic prostate cancer samples (red), mean CD45 levels in TRA þ cells are lower. Shown are the normalized mean and
standard deviation for one example per group. (B) shows the data set for healthy controls (blue), metastatic (red) and localized (gray) prostate cancer samples and for
the patient who progressed (orange) analyzing the normalized CD45 intensity differences calculated from TRA þ minus TRA-cells. Note that only samples were
included which contained at least three TRA þ cells. Positive differences indicate overall higher CD45 levels in TRA þ cells. (C) Receiver operating characteristics
(ROC) curves show diagnostic value and area under the curve comparing the CD45 intensity differences from healthy controls and metastatic prostate cancer patients
(black curve) and the differences from localized and metastatic prostate cancer patients (gray curve).
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negative for any detectable metastasis. This highlights the potential of
TRA-1-60 as a biomarker for metastatic cancer. Overall, the assay
described in our study has the potential to be translated into the clinic as
a blood-based diagnostic test to identify patients with life-threatening,
metastatic prostate cancer who would benefit from harsher treatment
options but also to reduce over-treatment and spare patients who show
localized disease. One could image that such an assay could be used as a
surveillance tool to monitor disease progression especially in patients
classified as Gleason 6 where treatment decisions are complex and
difficult. Our study provides preliminary basis for the usability of the
detection of TRAþ/CD45low cells to discriminate between localized and
metastatic prostate cancer patients. This study was performed on a
limited number of patients and further validations in bigger cohorts need
to be performed to evaluate the full potential of the approach. Further-
more, additional experiments would be required to define the nature of
this cellular phenotype especially interesting in this regard would be the
analysis of this cell population in chemotherapy naïve patient samples.
This would help answering the open question of the origin of the cell
population. Also, additional staining for prostate specific markers could
clarify if these cells disseminated from the primary prostate cancer.
Declarations
Author contribution statement
Claudia Schaefer: Conceived and designed the experiments; Per-
formed the experiments; Analyzed and interpreted the data; Wrote the
paper.
Yawen Ju, Youngbin Tak: Performed the experiments.
Cesar Vazquez, Edwin Tan: Contributed reagents, materials, analysis
tools or data.
Sangyoon J. Han: Analyzed and interpreted the data; Contributed
reagents, materials, analysis tools or data.
Jerry Shay, Mats Holmqvist, Gaudenz Danuser, William Schopperle:
Conceived and designed the experiments.
Glenn Bubley: Conceived and designed the experiments; Analyzed
and interpreted the data; Wrote the paper.
Funding statement
This work was performed in laboratories constructed with support
from NIH grant C06 RR30414 (J.W.S), the Harold Simmons NCI Desig-
nated Comprehensive Cancer Center Support Grant (CA142543) (J.W.S)
and the Cancer Prevention Institute of Texas (CPRIT) grant RP1225 (C.S.,
S.H., and G.D.).
Competing interest statement
YJ, YT, ET, MH and WMS are employed by CureMeta but were not
involved in the data collection and analysis. All other authors declare no
potential conflicts of interest.
Additional information
No additional information is available for this paper.
Acknowledgements
We would like to thank all patients and healthy donors who partici-
pated in this study.
References
[1] A.V. D'Amico, R. Whittington, S.B. Malkowicz, D. Schultz, K. Blank, G.A. Broderick,
et al., Biochemical outcome after radical prostatectomy, external beam radiation
therapy, or interstitial radiation therapy for clinically localized prostate cancer,
Jama 280 (11) (1998 Sep 16) 969–974. PubMed PMID: 9749478.
[2] T. Karantanos, P.G. Corn, T.C. Thompson, Prostate cancer progression after
androgen deprivation therapy: mechanisms of castrate resistance and novel
therapeutic approaches, Oncogene 32 (49) (2013 Dec 05) 5501–5511. PubMed
PMID: 23752182. Pubmed Central PMCID: 3908870.
[3] J.S. Frieling, D. Basanta, C.C. Lynch, Current and emerging therapies for bone
metastatic castration-resistant prostate cancer. Cancer control, J. Moffitt Canc. Cent.
22 (1) (2015 Jan) 109–120. PubMed PMID: 25504285. Pubmed Central PMCID:
4673894.
[4] R. Soundararajan, A.N. Paranjape, V. Barsan, J.T. Chang, S.A. Mani, A novel
embryonic plasticity gene signature that predicts metastatic competence and
clinical outcome, Sci. Rep. 5 (2015 Jun 30) 11766. PubMed PMID: 26123483.
Pubmed Central PMCID: 4485318.
[5] I. Ben-Porath, M.W. Thomson, V.J. Carey, R. Ge, G.W. Bell, A. Regev, et al., An
embryonic stem cell-like gene expression signature in poorly differentiated
aggressive human tumors, Nat. Genet. 40 (5) (2008 May) 499–507. PubMed PMID:
18443585. Pubmed Central PMCID: 2912221.
[6] J. Organista-Nava, Y. Gomez-Gomez, P. Gariglio, Embryonic stem cell-specific
signature in cervical cancer, Tumour Biol. : J. Int. Soci. Oncodevelopmental Biol.
Med. 35 (3) (2014 Mar) 1727–1738. PubMed PMID: 24163107.
[7] N.P. Palmer, P.R. Schmid, B. Berger, I.S. Kohane, A gene expression profile of stem
cell pluripotentiality and differentiation is conserved across diverse solid and
hematopoietic cancers, Genome Biol. 13 (8) (2012 Aug 21) R71. PubMed PMID:
22909066. Pubmed Central PMCID: 3491371.
[8] L.S. Z Peng, H. Hellborg, G. Jonstam, I.-L. Wingmo, M. Hj€alm-Eriksson,
U. Harmenberg, G.C. Cedermark, K. Andersson, L. Ah-R, S. Pramana, Y. Pawitan,
M. Nister, S. Nilsson, C. Li, An expression signature at diagnosis to estimate prostate
cancer patients’ overall survival, Prostate Canc. Prostatic Dis. (17) (2014) 81–90.
[9] P.W. Andrews, G. Banting, I. Damjanov, D. Arnaud, P. Avner, Three monoclonal
antibodies defining distinct differentiation antigens associated with different high
molecular weight polypeptides on the surface of human embryonal carcinoma cells,
Hybridoma 3 (4) (1984 Winter) 347–361. PubMed PMID: 6396197.
[10] W.M. Schopperle, W.C. DeWolf, The TRA-1-60 and TRA-1-81 human pluripotent
stem cell markers are expressed on podocalyxin in embryonal carcinoma, Stem Cells
25 (3) (2007 Mar) 723–730. PubMed PMID: 17124010.
[11] B. Iskender, K. Izgi, H. Karaca, H. Canatan, Myrtucommulone-A treatment decreases
pluripotency- and multipotency-associated marker expression in bladder cancer cell
line HTB-9, J. Nat. Med. 69 (4) (2015 Oct) 543–554. PubMed PMID: 26054707.
[12] K. Higashi, K. Asano, M. Yagi, K. Yamada, T. Arakawa, T. Ehashi, et al., Expression
of the clustered NeuAcalpha2-3Galbeta O-glycan determines the cell differentiation
state of the cells, J. Biol. Chem. 289 (37) (2014 Sep 12) 25833–25843. PubMed
PMID: 25074924. Pubmed Central PMCID: 4162184.
[13] D. Dang, D.M. Ramos, Identification of {alpha}v{beta}6-positive stem cells in oral
squamous cell carcinoma, Anticancer Res. 29 (6) (2009 Jun) 2043–2049. PubMed
PMID: 19528463.
[14] A. Siu, C. Lee, D. Dang, C. Lee, D.M. Ramos, Stem cell markers as predictors of oral
cancer invasion, Anticancer Res. 32 (4) (2012 Apr) 1163–1166. PubMed PMID:
22493345.
[15] M. Canham, C. Charsou, J. Stewart, S. Moncur, L. Hoodless, R. Bhatia, et al.,
Increased cycling cell numbers and stem cell associated proteins as potential
biomarkers for high grade human papillomavirusþve pre-neoplastic cervical
disease, PLoS One 9 (12) (2014), e115379. PubMed PMID: 25531390. Pubmed
Central PMCID: 4274002.
[16] V.K. Rajasekhar, L. Studer, W. Gerald, N.D. Socci, H.I. Scher, Tumour-initiating
stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling,
Nat. Commun. 2 (2011 Jan 18) 162. PubMed PMID: 21245843. Pubmed Central
PMCID: 3105310.
[17] D.C. Danila, G. Heller, G.A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, et
al., Circulating tumor cell number and prognosis in progressive castration-resistant
prostate cancer, Clin. Canc. Res. : An Off. J. Am. Assoc. Canc. Res. 13 (23) (2007
Dec 01) 7053–7058. PubMed PMID: 18056182.
[18] J.S. de Bono, H.I. Scher, R.B. Montgomery, C. Parker, M.C. Miller, H. Tissing, et al.,
Circulating tumor cells predict survival benefit from treatment in metastatic
castration-resistant prostate cancer, Clin. Cancer Res. : An Off. J. Am. Assoc. Canc.
Res. 14 (19) (2008 Oct 01) 6302–6309. PubMed PMID: 18829513.
[19] H.I. Scher, X. Jia, J.S. de Bono, M. Fleisher, K.J. Pienta, D. Raghavan, et al.,
Circulating tumour cells as prognostic markers in progressive, castration-resistant
prostate cancer: a reanalysis of IMMC38 trial data, Lancet Oncol. 10 (3) (2009 Mar)
233–239. PubMed PMID: 19213602. Pubmed Central PMCID: 2774131.
[20] Lei Xu, J. Shamash, Y.-J. Lu, Circulating tumor cells: a window to understand cancer
metastasis, monitor and fight against cancers, J. Cancer Res. Updates 4 (2015)
13–29.
[21] M. Ruscetti, B. Quach, E.L. Dadashian, D.J. Mulholland, H. Wu, Tracking and
functional characterization of epithelial-mesenchymal transition and mesenchymal
tumor cells during prostate cancer metastasis, Cancer Res. 75 (13) (2015 Jul 01)
2749–2759. PubMed PMID: 25948589. Pubmed Central PMCID: 4490048.
[22] K. Polyak, R.A. Weinberg, Transitions between epithelial and mesenchymal states:
acquisition of malignant and stem cell traits, Nat. Rev. Cancer 9 (4) (2009 Apr)
265–273. PubMed PMID: 19262571.
[23] J.P. Thiery, Epithelial-mesenchymal transitions in tumour progression, Nat. Rev.
Cancer 2 (6) (2002 Jun) 442–454. PubMed PMID: 12189386.
[24] G. Barriere, A. Riouallon, J. Renaudie, M. Tartary, M. Rigaud, Mesenchymal and
stemness circulating tumor cells in early breast cancer diagnosis, BMC Canc. 12
(2012 Mar 23) 114. PubMed PMID: 22443102. Pubmed Central PMCID: 3364860.
[25] T.M. Gorges, I. Tinhofer, M. Drosch, L. Rose, T.M. Zollner, T. Krahn, et al.,
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-
C. Sch€afer et al. Heliyon 6 (2020) e03263
7
mesenchymal transition, BMC Canc. 12 (2012 May 16) 178. PubMed PMID:
22591372. Pubmed Central PMCID: 3502112.
[26] D.S. Micalizzi, D.A. Haber, S. Maheswaran, Cancer metastasis through the prism of
epithelial-to-mesenchymal transition in circulating tumor cells, Mol. Oncol. 11 (7)
(2017 Jul) 770–780. PubMed PMID: 28544498. Pubmed Central PMCID: 5496489.
[27] M. Bulfoni, M. Turetta, F. Del Ben, C. Di Loreto, A.P. Beltrami, D. Cesselli, Dissecting
the heterogeneity of circulating tumor cells in metastatic breast cancer: going far
beyond the needle in the haystack, Int. J. Mol. Sci. (10) (2016 Oct 24) 17. PubMed
PMID: 27783057. Pubmed Central PMCID: 5085799.
[28] C. Sassetti, K. Tangemann, M.S. Singer, D.B. Kershaw, S.D. Rosen, Identification of
podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels
to CD34, J. Exp. Med. 187 (12) (1998 Jun 15) 1965–1975.
[29] D. Kerjaschki, L. Noronha-Blob, B. Sacktor, M.G. Farquhar, Microdomains of
distinctive glycoprotein composition in the kidney proximal tubule brush border,
JCB 98 (4) (1984) 1505.
[30] A. Somasiri, J.S. Nielsen, N. Makretsov, M.L. McCoy, L. Prentice, C.B. Gilks,
S.K. Chia, K.A. Gelmon, D.B. Kershaw, D.G. Huntsman, K.M. McNagny,
C.D. Roskelley, Overexpression of the anti-adhesin podocalyxin is an independent
predictor of breast cancer progression, Cancer Res. 64 (15) (2004 Aug 1)
5068–5073.
[31] R. Horvat, A. Hovorka, G. Dekan, H. Poczewski, D. Kerjaschki, Endothelial cell
membranes contain podocalyxin–the major sialoprotein of visceral glomerular
epithelial cells, J. Cell Biol. 102 (2) (1986 Feb) 484–491.
[32] Regis Doyonnas, Julie S. Nielsen, Shierley Chelliah, Erin Drew, Takahiko Hara,
Atsushi Miyajima, M. Kelly, McNagny, Podocalyxin is a CD34-related marker of
murine hematopoietic stem cells and embryonic erythroid cells, Blood 105 (2005)
4170–4178.
[33] Julia Fr€ose, Michelle B. Chen, Katie E. Hebron, Ferenc Reinhardt, Cynthia Hajal,
Andries Zijlstra, Roger D. Kamm, Robert A. Weinberg, Epithelial-mesenchymal
transition induces podocalyxin to promote extravasation via ezrin signaling, Cell
Rep. 24 (Issue 4) (24 July 2018) 962–972.
[34] C.L. Forse, Y.E. Yilmaz, D. Pinnaduwage, F.P. O'Malley, A.M. Mulligan, S.B. Bull,
I.L. Andrulis, Elevated expression of podocalyxin is associated with lymphatic
invasion, basal-like phenotype, and clinical outcome in axillary lymph node-
negative breast cancer, Breast Canc. Res. Treat. 137 (3) (2013 Feb) 709–719.
[35] D. Borg, C. Hedner, B. Nodin, A. Larsson, A. Johnsson, J. Eberhard, K. Jirstr€om,
Expression of podocalyxin-like protein is an independent prognostic biomarker in
resected esophagealandgastric adenocarcinoma,BMCClin. Pathol. 16 (2016Jul29)13.
C. Sch€afer et al. Heliyon 6 (2020) e03263
8
